Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin on atrial fibrillation after coronary artery bypass grafting
IRCT20250302064896N2Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dapagliflozin in Atrial fibrillation (AFib) and coronary arteriosclerosis, sponsored by Ahvaz Jundishapur University of Medical Sciences. Started May 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20250302064896N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250302064896N2.